Routine Use of Intravenous Low-Dose Recombinant Tissue Plasminogen Activator in Japanese Patients | Zendy

Ḱazunori Toyoda | Zendy; Masatoshi Koga | Zendy; Masaki Naganuma | Zendy; Yoshiaki Shiokawa | Zendy; Jyoji Nakagawara | Zendy; Eisuke Furui | Zendy; Kazumi Kimura | Zendy; Hiroshi Yamagami | Zendy; Yasushi Okada | Zendy; Yasuhiro Hasegawa | Zendy; Kazuomi Kario | Zendy; Satoshi Okuda | Zendy; Kazutoshi Nishiyama | Zendy; Kazuo Minematsu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Routine Use of Intravenous Low-Dose Recombinant Tissue Plasminogen Activator in Japanese Patients

Author(s) -

Ḱazunori Toyoda,

Masatoshi Koga,

Masaki Naganuma,

Yoshiaki Shiokawa,

Jyoji Nakagawara,

Eisuke Furui,

Kazumi Kimura,

Hiroshi Yamagami,

Yasushi Okada,

Yasuhiro Hasegawa,

Kazuomi Kario,

Satoshi Okuda,

Kazutoshi Nishiyama,

Kazuo Minematsu

Publication year - 2009

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.109.562991

Subject(s) - medicine , modified rankin scale , intracerebral hemorrhage , stroke (engine) , tissue plasminogen activator , thrombolysis , t plasminogen activator , surgery , ischemic stroke , ischemia , subarachnoid hemorrhage , mechanical engineering , engineering , myocardial infarction

A retrospective, multicenter, observational study was conducted to document clinical outcomes and to identify outcome predictors in patients treated with low-dose intravenous recombinant tissue plasminogen activator (0.6 mg/kg alteplase), which was approved in Japan in 2005, within 3 hours of stroke onset.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research